ObjectiveIn the present study, we investigated the role of brexpiprazole on cell proliferation and lipogenesis in colorectal cancer (CRC) and its molecular mechanism.MethodsThe effect of brexpiprazole on CRC cell proliferation was determined by CCK‐8, EdU assay, cell clone formation. The flow cytometry was evaluated cell cycle. Differential expression genes (DEGs) were identified by RNA‐seq assay after treating HCT116 cells with or without 20 μM brexpiprazole for 24 h. Then, the top 120 DEGs were analyzed by GO and KEGG enrichment analysis. After that, Oil red O staining and the levels of total cholestenone and triglyceride were measured to assess lipogenesis capacity in CRC cells. The related molecules of cell proliferation, lipogenic and AMPK/SREBP1 signal pathways were measured by q‐PCR, western blot and immunohistochemical staining.ResultsBrexpiprazole remarkably suppressed cell proliferation, lipogenesis, and induced cell cycle arrest in CRC. The underlying mechanisms probably involved the suppression of SREBP1 and the stimulation of AMPK.ConclusionBrexpiprazole inhibited cell proliferation and de novo lipogenesis through AMPK/SREBP1 pathway in CRC.
In the present study, we investigate the effect of brexpiprazole on cholesterol metabolism in colorectal cancer and its possible mechanism by transcriptome analysis andvalidation. Cell Counting Kit-8 (CCK-8) was used to detect the effect of brexpiprazole on the viability of colorectal cancer cells. Then, differential genes were identified by RNA-seq assay after treating colon cancer cells (HCT-116) with or without 20.0 μmol/L brexpiprazole for 24 h. After that, PPI network were constructed by the STRING database and Cytoscape to identify the top 120 hub genes, and then GO and KEGG enrichment analysis were measured. Differentially expressed protein and gene were measured by western blot and q-PCR, respectively. Finally, the mechanism of brexpiprazole regulating cholesterol metabolism in colorectal cancer was revealed through a series of in vitro and vivo experiments. The results of WB and q-PCR revealed that brexpiprazole significantly reduced the expression of HMGCR and HMGCS1. Besides, remarkable reduction of cellular Total Cholestenone (TC) levels in HCT-116 and SW620 cells after brexpiprazole treatment. Moreover, brexpiprazole also resulted in the restrained expression of p-PI3K, p-AKT, and SREBP2 in vivo and vitro.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.